John Crowley

John F. Crowley is a prominent biotechnology executive, currently serving as the President and CEO of the Biotechnology Innovation Organization (BIO), the largest biotechnology advocacy organization globally. He will officially assume this role on March 4, 2024, after stepping down from his position as Executive Chairman at Amicus Therapeutics, a company he co-founded in 2002 and led as CEO from 2005 until 2022.135

Early Life and Education

Born on April 7, 1967, Crowley's journey into biotechnology was deeply personal. His two children were diagnosed with Pompe disease, a severe neuromuscular disorder, which motivated him to shift from a career in financial consulting to the pharmaceutical industry. He graduated with a B.S. in Foreign Service from Georgetown University, followed by a J.D. from the University of Notre Dame Law School and an M.B.A. from the Harvard Business School.25

Career in Biotechnology

Crowley began his professional career at Bristol-Myers Squibb, where he worked in management before co-founding Novazyme Pharmaceuticals in 2000. This company focused on developing treatments for Pompe disease and was acquired by Genzyme Corporation in 2001, where he continued to lead efforts in developing enzyme replacement therapies for his children and others affected by the disease.245

In 2005, he founded Amicus Therapeutics, which has since grown into a significant player in the biotech industry, focusing on rare genetic diseases. Under his leadership, Amicus developed and marketed two notable drugs: Galafold for Fabry disease and Pombiliti for Pompe disease.134 Crowley has been recognized for his contributions to patient advocacy and biotechnology innovation.

Personal Life and Advocacy

Crowley's commitment to rare disease research stems from his family's experiences. His story was chronicled in the book The Cure by Geeta Anand and inspired the film Extraordinary Measures, featuring Brendan Fraser and Harrison Ford. He has also authored a memoir titled Chasing Miracles, detailing his family's journey through adversity.245

In addition to his corporate roles, Crowley served as an intelligence officer in the U.S. Navy Reserve from 2005 to 2016, participating in various special operations assignments.25 He is involved with several boards and organizations, including serving as a past National Chairman of the Make-A-Wish Foundation of America.

Recognition

Crowley has received numerous accolades for his work, including being named New Jersey's Entrepreneur of the Year and receiving honorary doctorates for his humanitarian efforts.6 His leadership at BIO comes at a critical time as the organization faces challenges related to drug pricing reforms and regulatory scrutiny within the biopharmaceutical sector.1

Overall, John F. Crowley's career reflects a blend of personal dedication to rare disease advocacy and professional success in biotechnology, making him a significant figure in both fields.